|
Dear Cure,
This year was a notable year for the Angelman syndrome community — one filled with excitement, some growing pains, frustrations, but most importantly, progress towards potential therapeutics for individuals living with Angelman syndrome.
Here’s a review of our year:
-
NIH announced a roughly $40m grant to Yale University to advance a novel CRISPR-based gene-editing delivery platform for the targeted treatment of neurogenetic diseases, Angelman syndrome being one of them.
-
FAST partnered with the University of Pennsylvania to develop an investigational adeno-associated virus (AAV) gene therapy for Angelman syndrome.
-
Ionis Pharmaceuticals and Ultragenyx Pharmaceuticals provided promising updates on their respective investigational ASO clinical trials.
- FAST has grown its staff, hiring four critical new staffers to support the operationalization of our mission.
-
The 16th Annual Global Science Summit & Gala was a success for so many reasons — save the date for next year’s event: Nov 8-9, 2024 in Orlando, FL!
-
We added FAST Poland to our list of global chapters!
- Our community did an amazing job raising funds through social media, hosting events, and peer-to-peer campaigns. We look forward to another successful year of Cure Angelman Now (CAN) fundraising — stay tuned in January 2024 for more details!
FAST is committed to exploring every available technology in gene-replacement, gene-editing, and disease-modifying therapies to advance therapies for Angelman syndrome.
Help us start 2024 with a bang by making your year-end gift to FAST today!
| 
